• Posted On Wednesday, April 6, 2022 by Evan Lamolinara

    Pharmaq12021

    SalesLeads announced today the Q1 2022 results for the new planned capital project spending report for the Pharmaceutical and BioTech industry. The Firm tracks North American planned industrial capital project activity including facility expansions, new plant construction and significant equipment modernization projects. Research confirms 89 new projects in the Pharmaceutical sector.

    Planned industrial project activity within the sector is down 9% YTD over the previous year.

    The following are selected highlights on new Pharmaceutical industry construction news.

    Pharmaceutical - By Project Type

              Manufacturing/Processing Facilities - 50 New Projects

              Laboratory Facilities - 33 New Projects

              Distribution and Industrial Warehouse - 24 New Projects

    Pharmaceutical - By Project Scope/Activity

              New Construction - 22 New Projects

              Expansion - 26 New Projects

              Renovations/Equipment Upgrades - 43 New Projects

              Plant Closing - 4 New Projects

    Pharmaceutical - By Project Location (Top 5 States)

              California - 17

              Massachusetts - 10

              North Carolina - 5

              Maryland - 4

              Virginia - 4

    Largest Planned Project

    During the 1st quarter of 2022, our research team identified 7 new Pharmaceutical facility construction projects with an estimated value of $100 million or more.

    The largest project is owned by Eli Lilly and Company, who is planning to invest $1 billion for the construction of a 5 building processing and manufacturing complex in CONCORD, NC. They have recently received approval for the project.

    Top 5 Tracked Pharmaceutical Projects

    MARYLAND:

    Medical supply company is planning to invest $350 million for the renovation and equipment upgrades on a 735,000 sf warehouse and manufacturing facility in SPARROWS POINT, MD. Completion is slated for early 2023.

    WISCONSIN:

    Biotechnology company is planning to invest $350 million for the construction of a 266,000 sf research and laboratory facility at 5505 Endeavor Lane in MADISON, WI. Completion is slated for 2024. The project includes an expansion of their existing warehouse and laboratory space at 1 Exact Lane in MADISON, WI.

    NORTH CAROLINA:

    Dietary supplement mfr. is expanding and planning to invest $177 million for the construction of a 230,000 distribution center at 208 Manufacturers Blvd. in MOORESVILLE, NC. The project includes the renovation and equipment upgrades on an existing 215,000 sf processing facility at the site.

    SOUTH CAROLINA:

    Startup biotechnology company is planning to invest $107 million for the renovation and equipment upgrades on a manufacturing facility at 260 Midway Drive in UNION, SC. Completion is slated for early 2023.

    NEW YORK:

    Pharmaceutical company is planning to invest $68 million for a 18,000 sf expansion and the renovation of their processing facility in SHIRLEY, NY. They have recently received approval for the project. Completion is slated for late 2023.

     

    About SalesLeads, Inc.

    Since 1959, SalesLeads, based in Jacksonville, FL is a leader in delivering industrial capital project intelligence and prospecting services for sales and marketing teams to ensure a predictable and scalable pipeline. Our Industrial Market Intelligence, IMI identifies timely insights on companies planning significant capital investments such as new construction, expansion, relocation, equipment modernization and plant closings in industrial facilities. The Outsourced Prospecting Services, an extension to your sales team, is designed to drive growth with qualified meetings and appointments for your internal sales team.


    Comment